Related Experiment Video

Updated: Sep 7, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

James E Frampton1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.

Targeted Oncology
|June 17, 2022
PubMed

Insights

Osimertinib significantly improves disease-free survival in early-stage, EGFR-mutated non-small cell lung cancer. This targeted therapy is well-tolerated and maintains quality of life for patients receiving adjuvant treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
  • Epidermal growth factor receptor (EGFR) mutations are key drivers in a subset of NSCLC patients.
  • Adjuvant therapy aims to eliminate residual disease and prevent recurrence after surgery.

Purpose of the Study:

  • To evaluate the efficacy and safety of osimertinib as adjuvant treatment for early-stage, EGFR-mutated NSCLC.
  • To assess the impact of osimertinib on disease-free survival (DFS) and overall survival (OS).
  • To determine the effect of osimertinib on health-related quality of life.

Main Methods:

  • The ADAURA trial was a pivotal study involving adult patients with resected, EGFRm+ NSCLC.
  • Patients received either osimertinib or placebo as adjuvant therapy.
  • Disease-free survival (DFS) was the primary endpoint, with overall survival (OS) as a key secondary endpoint.

Main Results:

  • Osimertinib significantly prolonged DFS in patients with stage IB-IIIA EGFR-mutated NSCLC compared to placebo.
  • The DFS benefit was observed across all stages (IB-IIIA) and was independent of prior adjuvant chemotherapy.
  • Osimertinib demonstrated a manageable safety profile and did not negatively impact quality of life.

Conclusions:

  • Osimertinib is an effective and well-tolerated targeted therapy for the adjuvant treatment of completely resected, early-stage, EGFR-mutated NSCLC.
  • The drug offers a significant DFS advantage, establishing it as a crucial option in the adjuvant setting.
  • Further mature overall survival data are anticipated with great interest.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K